دورية أكاديمية
أعرض في EDS

Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.

التفاصيل البيبلوغرافية
العنوان: Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.
المؤلفون: Kourek C; Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece., Briasoulis A; Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece., Papamichail A; Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece., Xanthopoulos A; Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece., Tsougos E; Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece., Farmakis D; Attikon University Hospital, Medical School of Athens, National and Kapodistrian University of Athens, 12462 Athens, Greece., Paraskevaidis I; Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 07; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 07.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Heart Failure*, Urea/*analogs & derivatives, Humans ; Stroke Volume ; Hydralazine/pharmacology ; Hydralazine/therapeutic use ; Isosorbide Dinitrate/pharmacology ; Isosorbide Dinitrate/therapeutic use ; Angiotensin Receptor Antagonists/pharmacology ; Multicenter Studies as Topic
مستخلص: Heart failure with reduced ejection fraction (HFrEF) is a complex clinical syndrome with significant morbidity and mortality and seems to be responsible for approximately 50% of heart failure cases and hospitalizations worldwide. First-line treatments of patients with HFrEF, according to the ESC and AHA guidelines, include β-blockers, angiotensin receptor/neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists. This quadruple therapy should be initiated during hospital stay and uptitrated to maximum doses within 6 weeks after discharge according to large multicenter controlled trials. Quadruple therapy improves survival by approximately 8 years for a 55-year-old heart failure patient. Additional therapeutic strategies targeting other signaling pathways such as ivabradine, digoxin, and isosorbide dinitrate and hydralazine combination for African Americans, as well as adjunctive symptomatic therapies, seem to be necessary in the management of HFrEF. Although second-line medications have not achieved improvements in mortality, they seem to decrease heart failure hospitalizations. There are novel medical therapies including vericiguat, omecamtiv mecarbil, genetic and cellular therapies, and mitochondria-targeted therapies. Moreover, mitraclip for significant mitral valve regurgitation, ablation in specific atrial fibrillation cases, omecamtiv mecarbil are options under evaluation in clinical trials. Finally, the HeartMate 3 magnetically levitated centrifugal left ventricular assist device (LVAD) has extended 5-year survival for stage D HF patients who are candidates for an LVAD.
References: Korean Circ J. 2022 Mar;52(3):173-197. (PMID: 35257531)
N Engl J Med. 2005 Jan 20;352(3):225-37. (PMID: 15659722)
Am J Med. 2019 Nov;132(11):1311-1319. (PMID: 31150644)
Congest Heart Fail. 2013 Jul-Aug;19(4):E40-5. (PMID: 23615021)
JAMA. 2022 Sep 27;328(12):1207-1209. (PMID: 36166048)
J Hypertens Suppl. 2006 Mar;24(1):S3-7. (PMID: 16601570)
P T. 2017 Jul;42(7):464-472. (PMID: 28674474)
Nat Med. 2011 Jan;17(1):71-8. (PMID: 21186368)
N Engl J Med. 2018 Aug 02;379(5):492. (PMID: 30067924)
Circulation. 2022 May 3;145(18):e895-e1032. (PMID: 35363499)
N Engl J Med. 1992 Sep 3;327(10):685-91. (PMID: 1463530)
Nat Rev Cardiol. 2017 Apr;14(4):238-250. (PMID: 28004807)
J Am Soc Nephrol. 2007 Jun;18(6):1953-8. (PMID: 17442790)
J Thorac Dis. 2018 Jun;10(Suppl 15):S1790-S1793. (PMID: 30034854)
Cochrane Database Syst Rev. 2021 Feb 03;(2):CD008684. (PMID: 35608922)
N Engl J Med. 1992 Sep 3;327(10):669-77. (PMID: 1386652)
Circ Arrhythm Electrophysiol. 2021 Jun;14(6):HAE0000000000000078. (PMID: 34129347)
J Am Heart Assoc. 2021 Aug 3;10(15):e020163. (PMID: 34320819)
N Engl J Med. 2004 Sep 23;351(13):1296-305. (PMID: 15385656)
Circulation. 2016 Sep 20;134(12):883-94. (PMID: 27489254)
Expert Rev Cardiovasc Ther. 2023 Feb;21(2):111-121. (PMID: 36680789)
N Engl J Med. 2020 Oct 8;383(15):1413-1424. (PMID: 32865377)
Lancet. 2022 Dec 3;400(10367):1938-1952. (PMID: 36356631)
Int J Cardiol Heart Vasc. 2019 Jun 26;24:100389. (PMID: 31304234)
N Engl J Med. 1987 Jun 4;316(23):1429-35. (PMID: 2883575)
N Engl J Med. 2004 Nov 11;351(20):2049-57. (PMID: 15533851)
Curr Treat Options Cardiovasc Med. 2017 Mar;19(3):23. (PMID: 28299616)
J Am Coll Cardiol. 2005 Apr 5;45(7):1051-60. (PMID: 15808763)
ESC Heart Fail. 2021 Dec;8(6):4617-4625. (PMID: 34498422)
Drugs. 1994;47 Suppl 4:47-57; discussion 57-8. (PMID: 7523062)
N Engl J Med. 2018 Dec 13;379(24):2307-2318. (PMID: 30280640)
N Engl J Med. 1999 Sep 2;341(10):709-17. (PMID: 10471456)
J Cardiovasc Pharmacol. 2023 Jan 01;81(1):4-14. (PMID: 36607775)
Redox Biol. 2020 Jul;34:101523. (PMID: 32273259)
Circ Res. 2013 Aug 30;113(6):646-59. (PMID: 23989710)
Handb Exp Pharmacol. 2017;243:465-490. (PMID: 28315072)
Circulation. 1998 Oct 27;98(17):1742-9. (PMID: 9788828)
Int J Cardiol Heart Vessel. 2014 Mar 19;3:6-14. (PMID: 29450163)
Expert Opin Ther Pat. 2016 Sep;26(9):1049-59. (PMID: 27455171)
Circ Res. 2014 Jun 20;115(1):44-54. (PMID: 24780171)
Circ Heart Fail. 2010 Jul;3(4):522-7. (PMID: 20498236)
Circulation. 2022 Jun 7;145(23):1705-1707. (PMID: 35858115)
Nat Commun. 2012 Apr 17;3:781. (PMID: 22510686)
N Engl J Med. 2023 Oct 12;389(15):1380-1389. (PMID: 37634135)
Am Fam Physician. 2017 Jan 1;95(1):13-20. (PMID: 28075105)
N Engl J Med. 2021 Jan 14;384(2):105-116. (PMID: 33185990)
Cureus. 2021 Jan 1;13(1):e12419. (PMID: 33542867)
Lancet. 2010 Sep 11;376(9744):886-94. (PMID: 20801495)
Curr Control Trials Cardiovasc Med. 2001;2(1):20-23. (PMID: 11806769)
J Am Coll Cardiol. 2002 Oct 16;40(8):1414-21. (PMID: 12392830)
Nat Rev Cardiol. 2017 Oct;14(10):591-602. (PMID: 28492288)
ISRN Cardiol. 2014 Feb 06;2014:652421. (PMID: 24653841)
JAMA. 2022 Sep 27;328(12):1233-1242. (PMID: 36074476)
Circulation. 2016 May 24;133(21):2066-75. (PMID: 27217432)
N Engl J Med. 2011 Jan 6;364(1):11-21. (PMID: 21073363)
J Cardiol. 2009 Oct;54(2):199-204. (PMID: 19782256)
N Engl J Med. 2023 Jun 1;388(22):2037-2048. (PMID: 36876756)
N Engl J Med. 1986 Jun 12;314(24):1547-52. (PMID: 3520315)
N Engl J Med. 2002 Mar 21;346(12):877-83. (PMID: 11907286)
Eur J Intern Med. 2020 Aug;78:95-100. (PMID: 32402562)
Bosn J Basic Med Sci. 2010 Apr;10 Suppl 1:S51-5. (PMID: 20433432)
Vasc Health Risk Manag. 2007;3(4):425-30. (PMID: 17969373)
Lancet. 2011 Aug 20;378(9792):676-83. (PMID: 21856481)
N Engl J Med. 2004 May 20;350(21):2140-50. (PMID: 15152059)
Sci Rep. 2021 Jul 5;11(1):13845. (PMID: 34226619)
J Am Soc Nephrol. 1995 Jun;5(12):2024-31. (PMID: 7579050)
Curr Heart Fail Rep. 2022 Apr;19(2):27-37. (PMID: 35147851)
N Engl J Med. 1997 Feb 20;336(8):525-33. (PMID: 9036306)
JACC Heart Fail. 2015 Mar;3(3):202-11. (PMID: 25650370)
Lancet. 2016 Dec 10;388(10062):2895-2903. (PMID: 27914656)
J Am Coll Cardiol. 2023 Mar 7;81(9):849-863. (PMID: 36858705)
Eur Heart J. 2021 Sep 21;42(36):3599-3726. (PMID: 34447992)
N Engl J Med. 2020 May 14;382(20):1883-1893. (PMID: 32222134)
Pharmacotherapy. 1998 Nov-Dec;18(6):1323-34. (PMID: 9855334)
Nat Commun. 2017 Aug 4;8(1):190. (PMID: 28775348)
N Engl J Med. 2002 Jun 13;346(24):1845-53. (PMID: 12063368)
Lancet. 2022 Sep 3;400(10354):757-767. (PMID: 36041474)
Eur Heart J. 2017 Feb 1;38(5):317-325. (PMID: 28201723)
Am J Pathol. 1990 Jul;137(1):7-12. (PMID: 2164777)
JAMA Cardiol. 2022 Jan 1;7(1):26-34. (PMID: 34643642)
JACC Heart Fail. 2014 Feb;2(1):84-92. (PMID: 24622121)
Int J Cardiol. 2020 May 1;306:102-108. (PMID: 32169347)
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):48-57. (PMID: 27530337)
N Engl J Med. 2018 Feb 01;378(5):417-427. (PMID: 29385358)
Lancet. 1999 Jan 2;353(9146):9-13. (PMID: 10023943)
JAMA. 2000 Mar 8;283(10):1295-302. (PMID: 10714728)
JCI Insight. 2017 Jul 20;2(14):. (PMID: 28724806)
Circulation. 2004 Jun 22;109(24):2942-6. (PMID: 15210610)
Cell Death Differ. 2015 Jun;22(6):1058-68. (PMID: 25501599)
فهرسة مساهمة: Keywords: HeartMate 3 left ventricular assist device (LVAD); angiotensin receptor/neprilysin inhibitors (ARNIs); heart failure with reduced ejection fraction (HFrEF); novel therapies; quadruple medical therapy; sodium-glucose co-transporter-2 inhibitors (SGLT2)
المشرفين على المادة: 2M19539ERK (omecamtiv mecarbil)
26NAK24LS8 (Hydralazine)
IA7306519N (Isosorbide Dinitrate)
0 (Angiotensin Receptor Antagonists)
8W8T17847W (Urea)
تواريخ الأحداث: Date Created: 20240328 Date Completed: 20240329 Latest Revision: 20240330
رمز التحديث: 20240330
مُعرف محوري في PubMed: PMC10969833
DOI: 10.3390/ijms25063113
PMID: 38542088
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25063113